The drug being tested in this study is TAK-058, which is under evaluation for the treatment of schizophrenia.~This study will enroll approximately 32 healthy non-elderly and 8 healthy elderly participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the five treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):~Cohort 1 Non-elderly Healthy: TAK-058 25 mg~Cohort 2 Non-elderly Healthy: TAK-058 75 mg~Cohort 3 Non-elderly Healthy: TAK-058 150 mg~Cohort 4 Elderly Healthy: TAK-058 25 mg~Cohort 5 Non-elderly Healthy: TAK-058 300 mg~Cohort 1-4 Non Elderly Placebo (dummy inactive solution) - this is an oral solution that looks like the study drug but has no active ingredient.~Cohort 5 Elderly Placebo This single-center trial will be conducted in the United States. The overall time to participate in this study is 40 days if assigned to Cohort 1 to 4. Participants will be confined to the clinic for 12 days, and will be contacted by telephone 11 and 30 days after last dose of study drug for a follow-up assessment (Days 21 and 40).~The overall time to participate in this study is 14 days if assigned to Cohort 5. Participants will be confined to the clinic for 4 days, and will be contacted by telephone 14 days after last dose of study drug for a follow-up assessment (Day 14).
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of TAK-058 in healthy non-elderly and elderly participants.